Bristol Myers Squibb (BMS) announced a number of forward-moving steps this week in its strategic pursuits within the global bio-tech industry. This includes successfully completing research collaboration with
Menten AI and exercising its option on
Prothena's PRX019, a neurodegenerative candidate.
FDA and
European Commission approvals were secured for
Opdivo and
Breyanzi, respectively, expanding their coverage and treatment indications. The company has also shown commitment to overall health equity through initiatives such as the
ASPIRE programme for low- and middle-income countries. Furthermore, BMS reportedly plans to launch
16 new products through 2030, as indicated by its CEO, Christopher Boerner. Despite facing setbacks, including a
data breach via Cencora and a significant financial hit in a
Plavix marketing case, BMS remains focused on future growth with the intent of augmenting its presence in multiple markets.
Bristol-Myers Squibb News Analytics from Tue, 03 Oct 2023 07:00:00 GMT to Thu, 30 May 2024 19:18:45 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -5
